FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110372244> ?p ?o ?g. }

• W2110372244 endingPage "4003" @default.
• W2110372244 startingPage "3996" @default.
• W2110372244 abstract "Purpose To determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma (DLBCL) and low-intermediate risk according to the International Prognostic Index when treated with dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) compared with standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). Patients and Methods Using immunohistochemistry, expression of CD10, BCL6, MUM1, MYC, and BCL2 and coexpression of MYC/BCL2 were examined. The interaction effects between each biomarker and treatment arm on survival were studied in a restricted model and a full model incorporating clinical parameters. Results Among the 379 patients analyzed in the trial, 229 tumors were evaluable for germinal center B-cell–like (GCB)/non-GCB subclassification according to the Hans algorithm. Among all the biomarkers, only the interaction between the Hans algorithm and the treatment arm was significant for progression-free survival (PFS) and overall survival (OS) in univariable (PFS, P = .04; OS, P = .01) and multivariable (PFS, P = .03; OS, P = .01) analyses. Non-GCB tumors predicted worse PFS (hazard ratio [HR], 3.21; 95% CI, 1.29 to 8.00; P = .01) and OS (HR, 6.09; 95% CI, 1.37 to 27.03; P = .02) among patients treated with R-CHOP compared with patients who received R-ACVBP, whereas there were no significant survival differences between these regimens among patients with GCB tumors. Conclusion The survival benefit related to R-ACVBP over R-CHOP is at least partly linked to improved survival among patients with non-GCB DLBCL. Therefore, the Hans algorithm could be considered a theragnostic biomarker for selecting young patients with DLBCL who can benefit from an intensified R-ACVBP immunochemotherapy regimen." @default.
• W2110372244 created "2016-06-24" @default.
• W2110372244 creator A5003078312 @default.
• W2110372244 creator A5003105021 @default.
• W2110372244 creator A5010990164 @default.
• W2110372244 creator A5012900514 @default.
• W2110372244 creator A5014546710 @default.
• W2110372244 creator A5014931705 @default.
• W2110372244 creator A5027607201 @default.
• W2110372244 creator A5027654738 @default.
• W2110372244 creator A5031041032 @default.
• W2110372244 creator A5033073385 @default.
• W2110372244 creator A5033149886 @default.
• W2110372244 creator A5036103172 @default.
• W2110372244 creator A5040629753 @default.
• W2110372244 creator A5049427985 @default.
• W2110372244 creator A5051581294 @default.
• W2110372244 creator A5052167942 @default.
• W2110372244 creator A5052452447 @default.
• W2110372244 creator A5062305482 @default.
• W2110372244 creator A5082700087 @default.
• W2110372244 creator A5085259120 @default.
• W2110372244 creator A5086354986 @default.
• W2110372244 creator A5089962133 @default.
• W2110372244 date "2014-12-10" @default.
• W2110372244 modified "2023-10-16" @default.
• W2110372244 title "Young Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B" @default.
• W2110372244 cites W1534776554 @default.
• W2110372244 cites W1966753131 @default.
• W2110372244 cites W1970400561 @default.
• W2110372244 cites W1976564639 @default.
• W2110372244 cites W1986599697 @default.
• W2110372244 cites W1993577803 @default.
• W2110372244 cites W1994719395 @default.
• W2110372244 cites W2006070956 @default.
• W2110372244 cites W2027633034 @default.
• W2110372244 cites W2058015212 @default.
• W2110372244 cites W2064208261 @default.
• W2110372244 cites W2067257663 @default.
• W2110372244 cites W2096984838 @default.
• W2110372244 cites W2103821553 @default.
• W2110372244 cites W2111530307 @default.
• W2110372244 cites W2111716055 @default.
• W2110372244 cites W2120415962 @default.
• W2110372244 cites W2125523937 @default.
• W2110372244 cites W2126779872 @default.
• W2110372244 cites W2133869962 @default.
• W2110372244 cites W2140485109 @default.
• W2110372244 cites W2142814377 @default.
• W2110372244 cites W2145304413 @default.
• W2110372244 cites W2147246240 @default.
• W2110372244 cites W2150587745 @default.
• W2110372244 cites W2153665789 @default.
• W2110372244 cites W2158267770 @default.
• W2110372244 cites W2159862107 @default.
• W2110372244 cites W2160305510 @default.
• W2110372244 cites W2163924431 @default.
• W2110372244 cites W2166900358 @default.
• W2110372244 cites W2171356556 @default.
• W2110372244 doi "https://doi.org/10.1200/jco.2013.54.9493" @default.
• W2110372244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25385729" @default.
• W2110372244 hasPublicationYear "2014" @default.
• W2110372244 type Work @default.
• W2110372244 sameAs 2110372244 @default.
• W2110372244 citedByCount "70" @default.
• W2110372244 countsByYear W21103722442015 @default.
• W2110372244 countsByYear W21103722442016 @default.
• W2110372244 countsByYear W21103722442017 @default.
• W2110372244 countsByYear W21103722442018 @default.
• W2110372244 countsByYear W21103722442019 @default.
• W2110372244 countsByYear W21103722442020 @default.
• W2110372244 countsByYear W21103722442021 @default.
• W2110372244 countsByYear W21103722442022 @default.
• W2110372244 countsByYear W21103722442023 @default.
• W2110372244 crossrefType "journal-article" @default.
• W2110372244 hasAuthorship W2110372244A5003078312 @default.
• W2110372244 hasAuthorship W2110372244A5003105021 @default.
• W2110372244 hasAuthorship W2110372244A5010990164 @default.
• W2110372244 hasAuthorship W2110372244A5012900514 @default.
• W2110372244 hasAuthorship W2110372244A5014546710 @default.
• W2110372244 hasAuthorship W2110372244A5014931705 @default.
• W2110372244 hasAuthorship W2110372244A5027607201 @default.
• W2110372244 hasAuthorship W2110372244A5027654738 @default.
• W2110372244 hasAuthorship W2110372244A5031041032 @default.
• W2110372244 hasAuthorship W2110372244A5033073385 @default.
• W2110372244 hasAuthorship W2110372244A5033149886 @default.
• W2110372244 hasAuthorship W2110372244A5036103172 @default.
• W2110372244 hasAuthorship W2110372244A5040629753 @default.
• W2110372244 hasAuthorship W2110372244A5049427985 @default.
• W2110372244 hasAuthorship W2110372244A5051581294 @default.
• W2110372244 hasAuthorship W2110372244A5052167942 @default.
• W2110372244 hasAuthorship W2110372244A5052452447 @default.
• W2110372244 hasAuthorship W2110372244A5062305482 @default.
• W2110372244 hasAuthorship W2110372244A5082700087 @default.
• W2110372244 hasAuthorship W2110372244A5085259120 @default.
• W2110372244 hasAuthorship W2110372244A5086354986 @default.
• W2110372244 hasAuthorship W2110372244A5089962133 @default.
• W2110372244 hasBestOaLocation W21103722441 @default.

• next